Electrolyte di sturbances that are managed to G rade 1 or less with supplemental therapy. A DLT will be considered related to HS -130/HS- 110 treatment unless there is a clear, well -documented, alternative explanation for the AE. AEs that meet the above criteria but occur after the DLT window of observation will not be defined as DLTs, but will be reported as AEs/Serious Adverse Events (SAEs), as applicable , and will be reviewed across all cohorts during the study to help inform dose escalation decisions. In case of suspicion of a DLT, the Investigator must inform the Medical Monitor/Sponsor immediately. The DLT will be confirmed by the Medica l Monitor/Sponsor and a decision must be taken by the S ponsor regarding if an ad hoc SRC meeting is required. Patients who are tolerating HS -130/HS -110 will not have to discontinue dosing prematurely due to the occurrence of DLTs in another patient in the same cohort, unless decided by the SRC. If requested by the Investigator, depending on the nature of the DLT and patient status, the SRC and the S ponso r may allow a patient to continue with study treatment at a reduced dose. Safety Review Committee (SRC) A Safety Review Committee (SRC) comprised of 3 members – one Investigator, a representative from Heat Biologi cs and the Medical M onitor , will evaluate the data obtained at each dose level and will recommend whether the dose should be escalated as per protocol, revised to a lower level or intermediate level, halted altogether or more patients are required at the same dose level to evaluate safety. Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 11 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page Duration of treatment: Upon completion of the first two treatment cycle s (i.e. 4-weeks with at least 2 doses of the combination treatment ), in the absence of disease progression and unacceptable toxicity, patients may continue to be treated w ith the combination of HS -130/ HS-110 at the same dose administered every 2 -weeks until disease progression, death, patient ’s withdrawal of consent, Investigator decision to discontinue treatment , or intolerable toxicity, whichever occurs first. At the discret ion of the I nvestigator the treatment with the therapeutic vaccines HS -130/HS -110 may continue despite evidence of disease progression as per Section 4.1. Criteria for evaluation: Study assessments are summa rized in the Schedule of Assessments. All screening proc edures will be performed within 28 days prior to the first dose, unless otherwise specified. Primary Endpoints • Safety and Tolerability: number of patients with TEAEs, SAEs, DLTs. Secondary Endpoints • Best overall response (CR, PR, SD), overall survival, PFS per RECIST 1.1 1. Exploratory Endpoints • Immunological effect assessed by evaluating proportions of natural killer (NK) and T cell subsets for levels of activation, memory and exhaustion using flow cytometry • Bioinformatics analysis of overexpressed CTAs and shared antigen expression with HS -110. • Immune reactivation response to HS -110 CTA -induced secretion of cytokines (e.g. by ELISPOT). • Changes in pro -inflammatory serum cytokines and chemokines, as well as non -specific inflammatory markers (e.g. C-reactive protein). • Genomic , immunohistochemical and proteomic analysis of pre -treatment and on -treatment biopsy (collected from patients within 5 -14 days after 2 nd dose of HS-130/HS -110) for exploratory biomarker analysis. • Immunologically active dose based on flow cytometry analysis of blood, using immune marker panels of activation and suppression as defined in S ection 8.6.1. Safety : • Safety will be assessed throughout the study by means of physical examination, weight, vital signs, performance status, laboratory evaluations (hematology, biochemistry including cytokines and chemokines), electrocardiogram (ECG), and recording of concurrent illness/therapy and treatment - emergent adverse events. CTCAE version 5 will be used to grade all toxicities. Patients will also be monitored for any clinical symptoms associated with elevated cytokine s levels. All related adverse events will be monitored until resolution or permanent outcome . Concomitant medications will be recorded throughout the study. Efficacy: • Response to treatment will be assessed according to RECIST 1.11. Objective evaluation will be performed at baseline and then every 8 -weeks ± 1-week. Exploratory: • Immune activation of peripheral blood mononuclear cells ( PBMCs ) for immunological effect will be determined from patient’s blood samples collected on Day 1 (p re-dose ) and Day 8 for Cycle 1 and Cycle 2, and on the 30- day safety follow -up visit . • Serum c ytokines and c hemokines using an ext ensive panel of marker s as described in Section 8.7, will be monitored at the time -points described below for Cycle 1 and Cycle 2 . Samples should also be collected and Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 12 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page analyzed for patient s that develop symptoms (i.e. flu -like symptoms , fever, or allergic reactions) at any time point for Cycle 3 and beyond. • Day 1: Pre -dose • Day 1: 2hr ± 10 minutes after last injection • Immune reactivation in response to CTA expressed in HS -110 (Section 8.6.2 ) and the immunologically active dose (Section 8.6.1 ) will be assessed from patient’s peri pheral blood samples collected on Day 1 ( pre-dose ) and Day 8 for Cycle 1 and Cycle 2 , and at 30- day safety follow -up visit . • Pre-treatment tumor samples and an on -treatment biopsy (collected from patients within 5 -14 days after 2nd dose of HS -130/HS- 110) will be analyzed for exploratory biomarkers . Statistical methods: All analyses will be descriptive.